BR112016022105A2 - - Google Patents
Info
- Publication number
- BR112016022105A2 BR112016022105A2 BR112016022105A BR112016022105A BR112016022105A2 BR 112016022105 A2 BR112016022105 A2 BR 112016022105A2 BR 112016022105 A BR112016022105 A BR 112016022105A BR 112016022105 A BR112016022105 A BR 112016022105A BR 112016022105 A2 BR112016022105 A2 BR 112016022105A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14161950 | 2014-03-27 | ||
EP14161950.2 | 2014-03-27 | ||
PCT/EP2015/056498 WO2015144799A1 (en) | 2014-03-27 | 2015-03-26 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016022105A2 true BR112016022105A2 (en) | 2017-08-15 |
BR112016022105B1 BR112016022105B1 (en) | 2023-01-31 |
Family
ID=50389872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016022105-2A BR112016022105B1 (en) | 2014-03-27 | 2015-03-26 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOL[1,5-A]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOL[1,5-A][1, 4]DIAZEPINE AS ROS1 INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THEM |
Country Status (13)
Country | Link |
---|---|
US (1) | US10280170B2 (en) |
EP (1) | EP3129376B1 (en) |
JP (1) | JP6522646B2 (en) |
KR (1) | KR102455519B1 (en) |
CN (1) | CN106164076B (en) |
AU (1) | AU2015238296B2 (en) |
BR (1) | BR112016022105B1 (en) |
CA (1) | CA2940918C (en) |
EA (1) | EA032255B1 (en) |
ES (1) | ES2715676T3 (en) |
IL (1) | IL247947B (en) |
MX (1) | MX367914B (en) |
WO (1) | WO2015144799A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6116782B1 (en) * | 2015-08-28 | 2017-04-19 | 積水メディカル株式会社 | Benzyl compounds |
TWI782056B (en) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | A fused ring derivative having a mgat2 inhibitoy activity |
CN112204027A (en) * | 2018-06-08 | 2021-01-08 | 贝达药业股份有限公司 | ERK inhibitor and application thereof |
JP7068743B2 (en) * | 2019-01-11 | 2022-05-17 | 塩野義製薬株式会社 | A pharmaceutical composition containing a condensed ring derivative having MGAT2 inhibitory activity. |
MX2021008050A (en) * | 2019-01-11 | 2021-08-05 | Shionogi & Co | Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity. |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2022072634A1 (en) * | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
CN114315866B (en) * | 2020-09-30 | 2023-10-31 | 烟台药物研究所 | Synthesis method of levamisole hydrochloride |
CN116744926A (en) * | 2020-12-15 | 2023-09-12 | 北京原基华毅生物科技有限公司 | Compounds as inhibitors of casein kinase |
CN114957259A (en) * | 2021-02-25 | 2022-08-30 | 南京明德新药研发有限公司 | Cyano-substituted aromatic bicyclic compound and application thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
US7662826B2 (en) | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
KR101050700B1 (en) | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Calcium receptor modulating compounds and uses thereof |
AU2003297431A1 (en) * | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
JP2005343889A (en) * | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | Imidazopyridine derivative |
JP2011506465A (en) * | 2007-12-12 | 2011-03-03 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Bactericidal bicyclic pyrazole |
WO2009086129A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth | Pyrazolo [1,5-a] pyrimidine compounds |
US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
US8518931B2 (en) * | 2008-04-07 | 2013-08-27 | Irm Llc | Compounds and compositions as kinase inhibitors |
MX2010010968A (en) | 2008-04-07 | 2010-10-26 | Irm Llc | Compounds and compositions as protein kinase inhibitors. |
WO2009140128A2 (en) * | 2008-05-13 | 2009-11-19 | Irm Llc | Compounds and compositions as kinase inhibitors |
CA2763631A1 (en) * | 2009-05-27 | 2010-12-02 | Abbott Laboratories | Pyrimidine inhibitors of kinase activity |
JP2012527970A (en) | 2009-05-28 | 2012-11-12 | クック メディカル テクノロジーズ エルエルシー | Hail-fastening device and hail-fastening device deployment method |
WO2011153553A2 (en) * | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
RU2014102935A (en) | 2011-08-02 | 2015-09-10 | Пфайзер Инк. | CRYZOTINIB FOR USE IN CANCER TREATMENT |
TWI585088B (en) * | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | Imidazo[1,2-b]pyridazine analogues as kinase inhibitors |
-
2015
- 2015-03-26 CA CA2940918A patent/CA2940918C/en active Active
- 2015-03-26 CN CN201580016470.XA patent/CN106164076B/en active Active
- 2015-03-26 JP JP2016559326A patent/JP6522646B2/en active Active
- 2015-03-26 AU AU2015238296A patent/AU2015238296B2/en active Active
- 2015-03-26 WO PCT/EP2015/056498 patent/WO2015144799A1/en active Application Filing
- 2015-03-26 BR BR112016022105-2A patent/BR112016022105B1/en active IP Right Grant
- 2015-03-26 US US15/129,582 patent/US10280170B2/en active Active
- 2015-03-26 ES ES15713436T patent/ES2715676T3/en active Active
- 2015-03-26 MX MX2016012668A patent/MX367914B/en active IP Right Grant
- 2015-03-26 EP EP15713436.2A patent/EP3129376B1/en active Active
- 2015-03-26 KR KR1020167028572A patent/KR102455519B1/en active IP Right Grant
- 2015-03-26 EA EA201691930A patent/EA032255B1/en not_active IP Right Cessation
-
2016
- 2016-09-21 IL IL247947A patent/IL247947B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
MX2016012668A (en) | 2016-12-14 |
EA201691930A1 (en) | 2017-02-28 |
ES2715676T3 (en) | 2019-06-05 |
BR112016022105B1 (en) | 2023-01-31 |
JP2017508779A (en) | 2017-03-30 |
CA2940918A1 (en) | 2015-10-01 |
CN106164076A (en) | 2016-11-23 |
AU2015238296B2 (en) | 2018-10-18 |
CA2940918C (en) | 2023-10-24 |
CN106164076B (en) | 2019-03-26 |
MX367914B (en) | 2019-09-11 |
US20170174690A1 (en) | 2017-06-22 |
EA032255B1 (en) | 2019-04-30 |
IL247947B (en) | 2019-03-31 |
US10280170B2 (en) | 2019-05-07 |
KR20160137576A (en) | 2016-11-30 |
WO2015144799A1 (en) | 2015-10-01 |
KR102455519B1 (en) | 2022-10-14 |
EP3129376B1 (en) | 2018-12-26 |
JP6522646B2 (en) | 2019-05-29 |
AU2015238296A1 (en) | 2016-09-08 |
EP3129376A1 (en) | 2017-02-15 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: CORRECAO NO QUADRO 1 DO PARECER DE DEFERIMENTO. |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/03/2015, OBSERVADAS AS CONDICOES LEGAIS |